Medidata (NASDAQ:MDSO) today announced its financial results for
the third quarter of 2018.
“Our strong financial and operational performance this quarter
highlight the momentum and success we are seeing in the market,”
said Tarek Sherif, chairman and chief executive officer, Medidata.
“Positive trends in the life sciences market around innovation and
operational efficiency are driving demand for Medidata’s
cloud-based solutions. Our impressive and rising win rate and
healthy backlog underscore the strength of Rave, as life sciences
companies and CROs adopt the Medidata Cloud to drive their digital
transformations.”
Third Quarter 2018 Results
- Total revenue was $163.4 million, an
increase of 18% compared with $138.9 million in the third quarter
of 2017
- Subscription revenue was $137.0
million, an increase of 17% compared with the same period last
year. Professional services revenue was $26.4 million, an increase
of 22% compared with the third quarter of 2017
- GAAP operating income was $14.1 million
and non-GAAP operating income1 was $41.4 million, representing a
GAAP and non-GAAP operating margin of 8.6% and 25.3%, respectively.
Both numbers reflect a full quarter of expenses related to the
acquisition and operations of SHYFT, which was acquired on June 20,
2018
- GAAP net income was $10.7 million, or
$0.17 per diluted share, compared with $13.0 million, or $0.22 per
diluted share, in the third quarter of 2017. Non-GAAP net income1
was $26.2 million, or $0.42 per diluted share, compared with $20.4
million, or $0.34 per diluted share, in the third quarter of 2017.
See the non-GAAP reconciliation included in this release for full
details of the non-GAAP adjustments
- Total cash and marketable securities
were $218.5 million at the end of the quarter, compared with $663.3
million on December 31, 2017
- Principal amount of $287.5 million
convertible notes was repaid with cash on August 1, 2018
- Remaining 2018 adjusted subscription
backlog2 as of September 30, 2018 was $139 million, an increase of
$22 million, or 19%, compared with a year ago
Additional Highlights:
- Penetration into APAC markets continues
to grow, highlighted by a platform agreement with the largest
pharmaceutical company in China and expansion deals with two of the
largest sponsors in Korea
- A record 24 Rave Patient Cloud deals
were closed this quarter, reaffirming the growing prominence of
mHealth solutions, as well as the unique value proposition of our
ePRO solution and its integration with Rave EDC
- The National Cancer Institute expanded
its agreement with Medidata, allowing it to double its number of
studies to 700 per year over the next five years, as it continues
to scale our nation’s support infrastructure for cancer
research
- Medidata’s revenue retention rate3 was
nearly 100%
“The third quarter highlights the strength and durability of our
business,” said Rouven Bergmann, chief financial officer, Medidata.
“We posted solid revenue growth, highlighted by subscription
revenue growth of 17%, and maintained a very healthy 25.3% EBITDAO
margin despite the dilutive impact of the SHYFT acquisition. We are
well positioned to achieve our 2018 plan.”
For the full year 2018, the company's guidance provided on June
12, 2018 is unchanged. Please refer to the reconciliation of
forward-looking guidance included in this release for full details
of the non-GAAP adjustments.
Conference call details:
Time: Today, October 18, 8 a.m. ET Conference ID:
5480999 Live dial-in: 1-877-303-2528, domestic
1-847-829-0023, international Webcast: investor.mdsol.com
Replay: 1-800-585-8367, domestic 1-404-537-3406,
international
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users everyday to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
Cautionary Statement
Certain statements made in this press release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 that involve significant
risks and uncertainties about Medidata Solutions, Inc.
(“Medidata”), including, but not limited to, statements about
Medidata’s forecast of financial performance, products and
services, business model, strategy and growth opportunities, and
competitive position. Such statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in these statements. Among
other things, the risks and uncertainties include those associated
with possible fluctuations in our financial and operating results;
integration activities, performance and financial impact of
acquired companies; our ability to retain and expand our customer
base or increase new business from those customers; and our ability
to continue to release, and gain customer acceptance of, new and
improved versions of our products. For additional disclosure
regarding these and other risks faced by Medidata, see disclosures
contained in Medidata’s public filings with the Securities and
Exchange Commission, including the “Risk Factors” section of
Medidata’s Annual Report on Form 10-K for the year ended December
31, 2017. You should consider these factors in evaluating the
forward-looking statements included in this press release and not
place undue reliance on such statements. The forward-looking
statements are made as of the date hereof, and Medidata undertakes
no obligation to update such statements as a result of new
information, new developments or otherwise, except as required by
law.
(1) Non-GAAP Financial Information
Medidata provides non-GAAP operating income, net income, and net
income per share data as a supplement to its operating results.
These measures are not in accordance with, or an alternative to,
generally accepted accounting principles (GAAP), and may be
different from non-GAAP measures used by other companies.
Management uses these non-GAAP measures to evaluate its financial
results, develop budgets, manage expenditures, and as an important
factor in determining variable compensation. In addition,
management believes, based on discussions with investors, that
these non-GAAP measures enhance investors’ ability to assess
Medidata’s historical and projected future financial performance.
While management believes these non-GAAP financial measures provide
useful supplemental information to investors, there are inherent
limitations associated with the use of non-GAAP financial measures.
Investors are encouraged to review the attached reconciliations of
these non-GAAP financial measures to the nearest comparable GAAP
measures.
(2) Adjusted subscription backlog equals subscription backlog
plus outstanding intra-year renewals valued at an amount equal to
the contracts to be renewed.
(3) Revenue retention rate is calculated as the percentage of
prior year revenue attributable to customers retained in the
current year.
MEDIDATA SOLUTIONS, INC. CONSOLIDATED STATEMENTS
OF OPERATIONS (Unaudited) (Amounts in thousands, except per
share data) Three Months Ended September 30,
Nine Months Ended September 30, 2018
2017 2018 2017 Revenues Subscription $
137,046 $ 117,271 (4) $ 394,351 $ 338,068 (4) Professional services
26,360 21,674 (4) 74,158 64,548 (4)
Total revenues 163,406 138,945 468,509 402,616 Cost of revenues
(1)(2) Subscription 24,618 17,131 66,561 51,277 Professional
services 17,609 14,423 49,469 42,811
Total cost of revenues 42,227 31,554 116,030 94,088 Gross profit
121,179 107,391 352,479 308,528 Operating costs and expenses
Research and development (1) 40,626 36,207 118,937 102,028 Sales
and marketing (1)(2) 38,329 29,996 (4) 112,296 92,701 (4) General
and administrative (1) 28,105 23,701 80,964 70,772 Wire transaction
recovery (3) — (4,770 ) — (4,770 ) Total operating
costs and expenses 107,060 85,134 312,197
260,731 Operating income 14,119 22,257 40,282 47,797
Interest and other income (expense) Interest expense (3,147 )
(4,407 ) (14,422 ) (13,117 ) Interest income 2,128 1,531 6,544
4,030 Other (expense) income, net (389 ) (7 ) 7,244 (7 )
Total interest and other expense, net (1,408 ) (2,883 ) (634 )
(9,094 ) Income before income taxes 12,711 19,374 39,648 38,703
Provision for income taxes 2,023 6,331 (4) 2,046
8,139 (4) Net income $ 10,688 $ 13,043
(4) $ 37,602 $ 30,564 (4) Earnings per share Basic $
0.18 $ 0.23 (4) $ 0.65 $ 0.54 (4)
Diluted $ 0.17 $ 0.22 (4) $ 0.62 $ 0.51
(4) Weighted average common shares outstanding Basic 58,680 56,654
57,734 56,389 Diluted 61,712 60,614 61,002 59,664 (1) Stock-based
compensation expense included in cost of revenues and operating
costs and expenses is as follows: Cost of revenues $ 1,918 $ 1,152
$ 4,692 $ 3,567 Research and development 2,988 3,472 9,161 9,734
Sales and marketing 3,732 1,864 9,293 4,875 General and
administrative 8,558 5,521 22,324 16,846
Total stock-based compensation $ 17,196 $ 12,009
$ 45,470 $ 35,022 (2) Amortization of
intangible assets included in costs of revenues and operating costs
and expenses is as follows: Cost of revenues $ 1,371 $ 1,094 $
3,670 $ 2,570 Sales and marketing 437 119 788
321 Total amortization of intangible assets $ 1,808 $
1,213 $ 4,458 $ 2,891 (3) Operating
costs and expenses for the three and nine months ended September
30, 2017 include recognition of insurance recovery of amounts
associated with the previously recognized 2014 wire transaction
loss. (4) Figures for the three and nine months ended September 30,
2017 have been recast to reflect our January 1, 2018 full
retrospective adoption of Accounting Standards Codification ("ASC")
606.
MEDIDATA SOLUTIONS, INC. Reconciliation of
GAAP Operating Income and GAAP Net Income to Non-GAAP
Operating Income and Non-GAAP Net Income (Unaudited)
(Amounts in thousands, except per share data)
Three Months Ended September 30, Nine
Months Ended September 30, 2018 2017
2018 2017 Operating income: GAAP
operating income $ 14,119 $ 22,257 (8) $ 40,282 $ 47,797 (8) GAAP
operating margins 8.6 % 16.0 % (8) 8.6 % 11.9 % (8) Stock-based
compensation 17,196 12,009 45,470 35,022 Depreciation and
amortization 9,118 6,853 25,336 16,918 Contingent consideration
adjustment (1) (270 ) 102 (263 ) 160 Cash compensation from
acquisition-related agreements (2) 1,238 — 1,372 — Wire transaction
recovery (3) — (4,770 ) — (4,770 ) Non-GAAP operating
income $ 41,401 $ 36,451 (8) $ 112,197 $
95,127 (8) Non-GAAP operating margins 25.3 % 26.2 % (8) 23.9
% 23.6 % (8) Net income: GAAP net income $ 10,688 $ 13,043 (8) $
37,602 $ 30,564 (8) Stock-based compensation 17,196 12,009 45,470
35,022 Amortization 1,808 1,213 4,458 2,891 Contingent
consideration adjustment (1) (270 ) 102 (263 ) 160 Cash
compensation from acquisition-related agreements (2) 1,238 — 1,372
— Wire transaction recovery (3) — (4,770 ) — (4,770 ) Interest
income on wire transaction recovery (4) (1,149 ) — (1,149 ) —
Non-cash interest expense (5) 1,861 3,698 9,732 10,944 Gain on step
acquisition (6) — — (7,648 ) — Tax impact on add-back items (7)
(5,171 ) (4,901 ) (12,993 ) (17,699 ) Non-GAAP net income $ 26,201
$ 20,394 (8) $ 76,581 $ 57,112 (8) GAAP
basic earnings per share $ 0.18 $ 0.23 (8) $ 0.65
$ 0.54 (8) GAAP diluted earnings per share $ 0.17
$ 0.22 (8) $ 0.62 $ 0.51 (8) Non-GAAP
basic earnings per share $ 0.45 $ 0.36 (8) $ 1.33
$ 1.01 (8) Non-GAAP diluted earnings per share $ 0.42
$ 0.34 (8) $ 1.26 $ 0.96 (8) (1)
Change in fair value of acquisition-related contingent
consideration liabilities. (2) Expense associated with
acquisition-related cash compensation agreements entered into with
certain employees of SHYFT Analytics, Inc. ("SHYFT"). (3) Operating
costs and expenses for the three and nine months ended September
30, 2017 include recognition of insurance recovery of amounts
associated with the previously recognized 2014 wire transaction
loss. We exclude these amounts for the purposes of calculating
non-GAAP operating income and non-GAAP net income because we
believe they are not indicative of our continuing operations or
meaningful when comparing current to past results. (4) Interest
income for the three and nine months ended September 30, 2018
includes interest on wire transaction recovery that was received
during the third quarter of 2018. We exclude this amount for the
purposes of calculating non-GAAP net income because we believe it
is not indicative of our continuing operations or meaningful when
comparing current to past results. (5) Non-cash interest expense
includes amortization of debt discount and issuance costs on our
1.00% convertible senior notes issued in 2013, which were converted
on August 1, 2018, and amortization of issuance costs on our credit
agreement entered into in 2017. We exclude this incremental
non-cash interest expense for purposes of calculating non-GAAP net
income. We believe that excluding these expenses from our non-GAAP
measures is useful to investors because such incremental non-cash
interest expense does not generate a cash outflow, nor do the debt
issuance costs represent a cash outflow except in the period of
issuance; therefore both are not indicative of our continuing
operations. (6) Elimination of gain recognized upon step
acquisition of SHYFT. (7) Tax impact calculated using tax rates of
25% and 40% for the periods ended September 30, 2018 and 2017,
respectively. (8) Figures for the three and nine months ended
September 30, 2017 have been recast to reflect our January 1, 2018
full retrospective adoption of ASC 606.
The table above presents a reconciliation
of GAAP to non-GAAP operating income, net income, and net income
per share applicable to common stockholders for the three and nine
months ended September 30, 2018 and 2017. Non-GAAP operating income
excludes the impact of stock-based compensation, depreciation,
amortization of intangible assets associated with acquisitions,
adjustments to the fair value of contingent consideration, cash
compensation from acquisition-related agreements, and wire
transaction recovery. Non-GAAP net income excludes the tax-affected
impact of stock-based compensation, amortization of intangible
assets associated with acquisitions, adjustments to the fair value
of contingent consideration, cash compensation from
acquisition-related agreements, wire transaction recovery and
interest thereon, non-cash interest expense, and gain on step
acquisition.
MEDIDATA SOLUTIONS, INC. CONSOLIDATED BALANCE
SHEETS (Unaudited) (Amounts in thousands, except per share
data) September 30, 2018
December 31, 2017
ASSETS Current assets: Cash and cash equivalents $ 83,496 $
237,325 Marketable securities 115,083 246,967 Accounts receivable,
net of allowance for doubtful accounts of $1,642 and $1,454,
respectively 163,180 110,685 Prepaid commission expense 18,422
12,404 Prepaid expenses and other current assets 27,898
33,636 Total current assets 408,079 641,017 Restricted cash
5,532 5,518 Furniture, fixtures and equipment, net 96,753 88,091
Marketable securities, long-term 19,878 179,041 Goodwill 215,000
47,435 Intangible assets, net 31,429 17,587 Deferred income taxes,
long-term 43,242 35,789 Other assets 47,875 46,755
Total assets $ 867,788 $ 1,061,233
LIABILITIES AND
STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $
6,661 $ 5,009 Accrued payroll and other compensation 36,639 32,537
Accrued expenses and other 40,195 36,041 Deferred revenue 78,464
77,375 1.00% convertible senior notes, net — 278,094
Total current liabilities 161,959 429,056 Noncurrent
liabilities: Term loan, net 89,512 92,841 Deferred revenue, less
current portion 2,901 5,256 Deferred tax liabilities 98 99 Other
long-term liabilities 19,332 21,371 Total noncurrent
liabilities 111,843 119,567 Total liabilities 273,802
548,623 Commitments and contingencies Stockholders'
equity: Preferred stock, par value $0.01 per share; 5,000 shares
authorized, none issued and outstanding — — Common stock, par value
$0.01 per share; 200,000 shares authorized; 65,888 and 62,801
shares issued; 61,194 and 58,607 shares outstanding, respectively
659 628 Additional paid-in capital 550,446 486,147 Treasury stock,
4,694 and 4,194 shares, respectively (152,216 ) (132,705 )
Accumulated other comprehensive loss (4,422 ) (3,377 ) Retained
earnings 199,519 161,917 Total stockholders' equity
593,986 512,610 Total liabilities and stockholders'
equity $ 867,788 $ 1,061,233
MEDIDATA
SOLUTIONS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) (Amounts in thousands) Nine Months
Ended September 30, 2018 2017 Cash flows
from operating activities Net income $ 37,602 $ 30,564 (1)
Adjustments to reconcile net income to net cash provided by
operating activities: Amortization of intangible assets and
depreciation 25,336 16,918 Stock-based compensation 45,470 35,022
Amortization of discounts or premiums on marketable securities 79
1,131 Realized loss on available-for-sale marketable securities 375
— Deferred income taxes (495 ) 6,035 (1) Amortization of debt
issuance costs 1,071 958 Amortization of debt discount 8,661 9,986
Provision for doubtful accounts 1,169 806 Loss (gain) on fixed
asset disposal 399 (8 ) Gain recognized on step acquisition (7,648
) — Changes in fair value of contingent consideration (263 ) 160
Changes in operating assets and liabilities: Accounts receivable
(53,664 ) 9,050 Prepaid commission expense (11,208 ) (8,157 ) (1)
Prepaid expenses and other current assets 6,113 (16,187 ) (1) Other
assets 774 596 Accounts payable 3,510 (3,796 ) Accrued payroll and
other compensation 1,191 (3,155 ) Accrued expenses and other 6,394
3,539 Deferred revenue (4,275 ) 7,111 (1) Other long-term
liabilities (3,344 ) 1,001 Net cash provided by operating
activities 57,247 91,574 Cash flows from investing
activities Purchase of furniture, fixtures and equipment (28,929 )
(30,502 ) Purchase of available-for-sale securities (69,214 )
(224,291 ) Proceeds from sale of available-for-sale securities
360,272 220,059 Acquisition of businesses, net of cash acquired
(179,063 ) (22,941 ) Net cash provided by (used in) investing
activities 83,066 (57,675 ) Cash flows from financing
activities Proceeds from exercise of stock options 12,169 9,675
Proceeds from employee stock purchase plan 9,507 6,799 Acquisition
of treasury stock (19,509 ) (16,293 ) Repayment of convertible
notes (287,500 ) — Term loan principal payments (3,750 ) — Payment
of acquisition-related earn-outs (4,417 ) — Payment of credit
facility financing costs (175 ) — Net cash (used in)
provided by financing activities (293,675 ) 181 Effect of
exchange rate changes on cash, cash equivalents and restricted cash
(453 ) 591 Net (decrease) increase in cash, cash equivalents
and restricted cash (153,815 ) 34,671 Cash, cash equivalents and
restricted cash – Beginning of period 242,843 99,279
Cash, cash equivalents and restricted cash – End of period $ 89,028
$ 133,950 (1) Figures for the nine months ended
September 30, 2017 have been recast to reflect our January 1, 2018
full retrospective adoption of ASC 606.
MEDIDATA
SOLUTIONS, INC. Reconciliation of Forward-Looking GAAP
Operating Income Guidance and GAAP Net Income Guidance to
Non-GAAP Operating Income Guidance and Non-GAAP Net Income
Guidance (Unaudited) (Amounts in millions)
Estimated Full-Year 2018
Total revenues $624.0 - $648.0 GAAP operating income:
$45.5- $53.5 Stock-based compensation (1) 64.0 Depreciation and
amortization (1) 34.0 Contingent consideration adjustment (1) 0.5
Cash compensation from acquisition-related agreements (1) 2.0
Non-GAAP operating income $146.0 - $154.0 GAAP
net income: $28.5 - $35.5 Stock-based compensation (1) 64.0
Amortization (1) 6.0 Non-cash interest expense (1) 10.0 Contingent
consideration adjustment (1) 0.5 Cash compensation from
acquisition-related agreements (1) 2.0 Tax impact on add-back items
(2) (20.5 ) Non-GAAP net income $90.5 - $97.5 Fully
diluted share count 61.0 (1) Represents the estimated
midpoint of our guidance range. (2) Tax impact estimated using a
25% rate.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181018005241/en/
MedidataInvestors:Betsy Frank,
917-522-4620bfrank@mdsol.comorMedia:Erik Snider,
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024